West Pharmaceutical Services (NYSE:WST) Releases Quarterly Earnings Results, Beats Expectations By $0.45 EPS

West Pharmaceutical Services (NYSE:WST) posted its quarterly earnings data on Thursday. The medical instruments supplier reported $2.13 earnings per share for the quarter, beating analysts’ consensus estimates of $1.68 by $0.45, Zacks reports. West Pharmaceutical Services had a return on equity of 17.90% and a net margin of 16.06%.The firm’s revenue for the quarter was up 21.0% on a year-over-year basis. During the same period in the prior year, the business earned $1.45 earnings per share. West Pharmaceutical Services updated its FY 2026 guidance to 8.400-8.750 EPS and its Q2 2026 guidance to 2.050-2.120 EPS.

Here are the key takeaways from West Pharmaceutical Services’ conference call:

• West reported a strong Q1 with revenues of $845M (+21% reported, +15% organic) and adjusted EPS of $2.13, and raised full?year guidance to 7%–9% organic revenue growth and $8.40–$8.75 adjusted EPS.
• HVP components remain the main growth engine—organic HVP components growth was ~23%, GLP?1s represented ~10% of company sales, biologics were up 26%, and Annex I / HVP conversion is expected to add ~200 bps to revenue growth in 2026.
• Margins and capital returns improved: adjusted operating margin expanded to 21.4% ( +350 bps Y/Y), the board authorized a $1B share buyback and the company repurchased $298M of shares in Q1.
• Near?term headwinds include a ~$40M CGM contract roll?off in H2, and rising oil/commodity costs (management expects a net impact of low?single?digit millions after mitigation), which could pressure second?half cadence and margins.

West Pharmaceutical Services Trading Up 12.8%

WST traded up $35.16 during trading on Thursday, hitting $309.57. The company’s stock had a trading volume of 1,219,318 shares, compared to its average volume of 962,462. The firm has a market capitalization of $22.31 billion, a P/E ratio of 45.46, a PEG ratio of 2.92 and a beta of 1.15. West Pharmaceutical Services has a twelve month low of $199.89 and a twelve month high of $322.34. The stock’s fifty day moving average price is $250.67 and its 200-day moving average price is $261.77. The company has a quick ratio of 2.34, a current ratio of 3.02 and a debt-to-equity ratio of 0.06.

West Pharmaceutical Services Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 6th. Investors of record on Wednesday, April 29th will be paid a dividend of $0.22 per share. The ex-dividend date of this dividend is Wednesday, April 29th. This represents a $0.88 annualized dividend and a yield of 0.3%. West Pharmaceutical Services’s dividend payout ratio (DPR) is currently 12.96%.

Hedge Funds Weigh In On West Pharmaceutical Services

Several institutional investors have recently made changes to their positions in the stock. CYBER HORNET ETFs LLC acquired a new stake in shares of West Pharmaceutical Services in the 2nd quarter valued at about $25,000. DV Equities LLC acquired a new position in West Pharmaceutical Services during the 4th quarter worth approximately $28,000. MUFG Securities EMEA plc bought a new position in West Pharmaceutical Services in the second quarter worth approximately $47,000. State of Wyoming bought a new position in West Pharmaceutical Services in the second quarter worth approximately $49,000. Finally, Meeder Asset Management Inc. grew its stake in West Pharmaceutical Services by 1,023.5% in the fourth quarter. Meeder Asset Management Inc. now owns 191 shares of the medical instruments supplier’s stock valued at $53,000 after acquiring an additional 174 shares during the period. Institutional investors and hedge funds own 93.90% of the company’s stock.

Analyst Upgrades and Downgrades

WST has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $315.00 price target on shares of West Pharmaceutical Services in a research note on Friday, February 13th. Zacks Research lowered West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, April 14th. UBS Group reiterated a “buy” rating and issued a $340.00 target price on shares of West Pharmaceutical Services in a report on Friday, February 13th. Jefferies Financial Group reissued a “buy” rating and set a $295.00 target price on shares of West Pharmaceutical Services in a research report on Tuesday, February 10th. Finally, Evercore dropped their price target on shares of West Pharmaceutical Services from $390.00 to $320.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 3rd. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, West Pharmaceutical Services has a consensus rating of “Moderate Buy” and a consensus price target of $315.67.

Key Stories Impacting West Pharmaceutical Services

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Q1 results materially beat expectations — EPS $2.13 vs. consensus $1.68 and revenue grew ~21% year-over-year, signaling solid top- and bottom-line momentum. Compared to Estimates, West Pharmaceutical (WST) Q1 Earnings
• Positive Sentiment: Company raised FY2026 guidance (EPS to $8.40–$8.75 and revenue to $3.3–$3.4B) and raised Q2 guidance, which supports higher near?term earnings expectations. West Reports First-Quarter 2026 Results
• Positive Sentiment: Management cites strong demand for its proprietary packaging components (syringes, cartridges) as the driver of the beat and outlook lift — a structural end-market tailwind that supports sustained revenue growth. West Pharma lifts 2026 profit forecast
• Positive Sentiment: Street reaction and headlines show the stock jumped on the news, reflecting investor enthusiasm for the beat + guide combo. West Pharma Stock Jumps
• Neutral Sentiment: Key profitability metrics are healthy (ROE ~17.9%, net margin ~16%), but valuation is elevated (PE ~45.6), which could temper upside unless growth continues to outpace expectations.
• Neutral Sentiment: Investor materials and the conference call / slide deck are available for more detail on drivers and cadence; these may influence guidance clarity and near-term sentiment. Q1 Slide Deck

West Pharmaceutical Services announced that its Board of Directors has authorized a share buyback program on Tuesday, February 17th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the medical instruments supplier to repurchase up to 5.6% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s board believes its stock is undervalued.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.